ArborGen and Senesco Announce Wood Quality Results

SUMMERVILLE, S.C., July 7 /PRNewswire/ -- ArborGen, LLC, a leader in forest
tree improvement technologies, today announced wood quality results from
ongoing field trials that are utilizing technology in-licensed from Senesco
Technologies, Inc. (NYSE AMEX: SNT). The two companies had previously
announced that trees that incorporate Senesco technology have shown
significantly enhanced growth rates in 3-year-old field trials.

Selected trees from the field trials were harvested and their wood chemistry
and density was assessed. There were no differences in key economic
characteristics of wood, such as lignin, cellulose, and specific gravity,
between the trees with the enhanced growth attributes and untreated control
trees. This is good news as fast tree growth is often associated with lower
wood quality.

"With several years of positive field trials, Senesco's technology has
certainly given us confidence in the consistency of performance of this
technology," said Barbara Wells, Ph.D., president and CEO of ArborGen. "Our
collaboration with Senesco continues to produce very promising results that we
expect will ultimately add to our portfolio of forestry products."

Bruce Galton, President and CEO of Senesco, said, "We believe ArborGen's
results represent another step toward the commercial validation of our
technology in the hands of our licensing partners. Partnering with companies
with ArborGen's expertise allows for development of our technology for
agricultural applications, while our internal research and development remains
focused on our near term goal of filing an Investigational New Drug
application with the FDA for our ongoing oncology work in multiple myeloma.
We believe these results further reaffirm the broad applicability of Senesco's
technology."

About ArborGen, LLC

ArborGen is a leader in tree improvement and the commercial production of
trees. We are dedicated to helping the global forest industry meet the growing
demand for wood, pulp & paper, and energy in a more productive and sustainable
way. Enabling more wood to be grown on less land helps conserve the world's
native forests in all their beauty, diversity and complexity. With one of the
world's most extensive tree germplasm resources, ArborGen uses both
traditional breeding and advanced genetic technologies, to discover and
produce high yield seedlings for our customers, allowing our customers to
significantly increase the productivity of their forests and manufacturing
processes. Our mission is to deliver superior performing trees through
innovative science and world class customer service -- every tree, every time.
For more information, please visit www.arborgen.com.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in
New Brunswick, NJ. Senesco has initiated preclinical research to trigger or
delay cell death in mammals (apoptosis) to determine if the technology is
applicable in human medicine. Accelerating apoptosis may have applications to
development of cancer treatments. Delaying apoptosis may have applications to
certain inflammatory and ischemic diseases. Senesco takes its name from the
scientific term for the aging of plant cells: senescence. Delaying cell
breakdown in plants extends freshness after harvesting, while increasing crop
yields, plant size and resistance to environmental stress. The Company
believes that its technology can be used to develop superior strains of crops
without any modification other than delaying natural plant senescence.
Senesco has partnered with leading-edge companies engaged in agricultural
biotechnology and earns research and development fees for applying its
gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Actual results could differ materially from such statements
expressed or implied herein as a result of a variety of factors, including,
but not limited to: the ability of Senesco to consummate a financing; the
development of Senesco's gene technology; the approval of Senesco's patent
applications; the successful implementation of Senesco's research and
development programs and joint ventures; the success of Senesco's license
agreements; the acceptance by the market of Senesco's products; success of
Senesco's preliminary studies and preclinical research; competition and the
timing of projects and trends in future operating performance, Senesco's
ability to meet its funding milestones under its financing transaction,
Senesco's ability to continue to comply with the continued listing standards
of the AMEX, as well as other factors expressed from time to time in Senesco's
periodic filings with the Securities and Exchange Commission (the "SEC"). As
a result, this press release should be read in conjunction with Senesco's
periodic filings with the SEC. The forward-looking statements contained
herein are made only as of the date of this press release, and Senesco
undertakes no obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.

Senesco Investor Contact:
Brian Ritchie
FD
Phone: (212) 850-5600
E-mail: brian.ritchie@fd.com

ArborGen Contact:
Nancy M. Hood
Director of Communication & Public Affairs
Phone: (843) 851-5077
Cell: (843) 323-1509
E-mail: nmhood@arborgen.com

SOURCE ArborGen, LLC

Investors, Brian Ritchie of FD, for Senesco, +1-212-850-5600,
brian.ritchie@fd.com; or Nancy M. Hood, Director of Communication & Public
Affairs of ArborGen, +1-843-851-5077, Cell, +1-843-323-1509,
nmhood@arborgen.com